Results 31 to 40 of about 6,036 (190)
Abciximab in Acute Ischemic Stroke
, 2000 Background and Purpose —Abciximab is a potent parenterally administered platelet glycoprotein IIb/IIIa antagonist. Because this agent has been shown to improve outcomes in coronary artery disease, there is interest to evaluate ...
The Abciximab in Ischemic Stroke Investigators +1 more
core +1 more source
Rationale for intracoronary administration of abciximab
, 2007 The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes ...
Trani C. +3 more
core +2 more sources
The use of combination of fibrinolytic therapy and abciximab in the treatment of the acute myocardial infarction with ST elevation [PDF]
Vojnosanitetski Pregled, 2002 Background. According to current knowledge, the best way to treat the acute myocardial infarction with ST elevation is primary transluminal coronary angioplasty, which can be performed only in the best equipped tertiary cardiology centers.
Gligić Branko +4 more
doaj +1 more source
Intracoronary abciximab in STEMI using local drug delivery catheter – Single center experience
Indian Heart Journal, 2013 Background: Despite restoration of epicardial flow during primary PCI in STEMI, microvascular obstruction may persist as a result of both atheromatous and thrombotic embolization and vasospasm.
G. Sengottuvelu, V. Ravi Sekar
doaj +1 more source
Abciximab-induced delayed profound thrombocytopaenia
, 2017 No commercial use is permitted unless otherwise expressly granted. Abciximab, the first approved glycoprotein (GP IIb/IIIa) inhibitor, is being widely used during acute coronary syndromes and offers the promising approach to antithrombotic therapy.
Kailash Bajaj +7 more
core +1 more source
A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results [PDF]
, 2003 Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making.
Reed, S.D. +4 more
core +1 more source
Cardiovascular Ultrasound, 2012 Background Embolization of atherosclerotic debris from the rupture of a vulnerable atherosclerotic plaque occurs iatrogenically during percutaneous coronary interventions (PCI) and can induce myocardial necrosis.
Kretzschmar Daniel +9 more
doaj +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma +8 more
wiley +1 more source
Bilateral subconjunctival hemorrhage secondary to abciximab use: case report
, 2019 CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
Muhammet Raşit Sayın (4701283) +1 more
core +1 more source
Acta Ortopédica Brasileira, 2000 O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj +1 more source